Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Redbiotec, GE Healthcare CMV Vaccine Collaboration

Published: Tuesday, August 05, 2014
Last Updated: Tuesday, August 05, 2014
Bookmark and Share
Companies combine expertise to produce cytomegalovirus vaccine candidates.

Redbiotec has successfully applied its unique expertise and innovative technology platform to complete a collaborative program with global multinational, GE Healthcare Life Sciences. Using GE Healthcare's single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a novel process for the production, clarification, and concentration of cytomegalovirus-like particles. Results from the study have recently been published1, further substantiating the value of the Redbiotec rePAX® platform for the development and production of new vaccines against cytomegalovirus (CMV).
 
Redbiotec uses its proprietary rePAX® co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. This technology is effectively applied to both in-house and external co-development programs, supporting the company’s mission to discover and develop novel, effective vaccines against the highly prevalent influenza and herpes viruses.
 
Commenting on the collaboration, Jakob Liderfelt, Section Manager Cell Culture, LS Bio Process GE Healthcare Life Sciences, said, “GE Healthcare Life Sciences seeks to collaborate with world-wide biotechnology leaders such as Redbiotec to help drive disease research forward. We are looking forward to continuing our work with the company to help advance their CMV program using our next-generation WAVE Bioreactor system. This system was specifically developed to enable the fast and scalable production of biopharmaceuticals such as Redbiotec’s virus-like particles."
Christian Schaub, CEO of Redbiotec commented, “Our unique rePAX® technology allows us to successfully replicate viral structures or even whole viruses. Importantly, these natural, virus-like particles (reVLPs®) are functional but non-replicating, rendering them non-hazardous and allowing us to apply them to vaccine development. The vaccine will then stimulate an immune response without causing infectious disease.” He continued, ”Collaborations such as this project with GE Healthcare enable us to develop CMV-like particles and soluble CMV protein complexes at an industrial scale for the pre-clinical and clinical trials of vaccines.”
 
This latest news follows recent partnership announcements with Roche, GSK and Merck, positioning Redbiotec as an important innovator in the development of novel vaccines to alleviate unmet medical needs and improve the lives of patients. To learn more, visit www.redbiotec.ch.
 
1 Vicente T, Burri S, Wellnitz S, Walsh K, Rothe S, Liderfelt J (2014) Fully aseptic single-use cross flow filtration system for clarification and concentration of cytomegalovirus-like particles; Engineering in Life Sciences 14:318–26.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!